Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI

Kargbo, Robert B.

doi:10.1021/acsmedchemlett.3c00333

ACS Med. Chem. Lett.

2023

DOI: 10.1021/acsmedchemlett.3c00333

|View full text |Cite

Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI

Robert B. Kargbo

Abstract: This viewpoint discusses integrating biomarkers, psychedelics, and AI into psychiatry for enhanced diagnostics, prognosis, and treatment. It highlights the potential of psychedelics in therapy, AI's role in predicting treatment response, and the challenges that must be addressed. The aim is to encourage research for more precise, personalized psychiatric care.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Artificial intelligence and psychedelic medicine

Sarris,

Halman,

Urokohara

et al. 2024

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Artificial intelligence (AI) and psychedelic medicines are among the most high‐profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. In order to inform our perspective, we conducted a scoping review of relevant literature up to late August 2024 via PubMed intersecting AI with psychomedical use of psychedelics. Our perspective covers the potential application of AI in psychedelic medicine for: drug discovery and clinical trial optimization (including pharmacodynamics); study design; understanding psychedelic experiences; personalization of treatments; clinical screening, delivery, and follow‐up (potentially delivered via chatbots/apps); application of psychological preparation, integration, and general mental health support; its role in enhancing treatment via brain modulatory devices (including virtual reality and haptic suits); and the consideration of ethical and security safeguards. Challenges include the need for sufficient data protection and security, and a range of necessary ethical protections. Future avenues of exploration could involve directly administering psychedelics (or providing algorithm‐generated effects) to inorganic AI‐interfaced neural networks that may exceed human brain activity (i.e., cognitive capacity) and intelligence.

show abstract

Artificial intelligence and psychedelic medicine

Sarris,

Halman,

Urokohara

et al. 2024

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI

Cited by 1 publication

References 25 publications

Artificial intelligence and psychedelic medicine

Artificial intelligence and psychedelic medicine

Contact Info

Product

Resources

About